S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   9634
 
                           I N  A S S E M B L Y
 
                             January 28, 2020
                                ___________
 
 Introduced by M. of A. L. ROSENTHAL, QUART, RICHARDSON, CARROLL, WEPRIN,
   SIMON, GOTTFRIED, HEVESI -- read once and referred to the Committee on
   Health
 
 AN  ACT  to  amend the social services law and the public health law, in
   relation to medication for the treatment of substance use disorders
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section  1.  Subdivision 2 of section 365-a of the social services law
 is amended by adding a new paragraph (gg) to read as follows:
   (GG) ALL BUPRENORPHINE PRODUCTS, METHADONE OR LONG  ACTING  INJECTABLE
 NALTREXONE  FOR  DETOXIFICATION  OR MAINTENANCE TREATMENT OF A SUBSTANCE
 USE DISORDER PRESCRIBED ACCORDING TO GENERALLY ACCEPTED NATIONAL PROFES-
 SIONAL GUIDELINES FOR THE TREATMENT OF A SUBSTANCE USE DISORDER.    SUCH
 MEDICATION ASSISTED TREATMENT SHALL NOT BE SUBJECT TO ANY PRIOR AUTHORI-
 ZATION MANDATE.
   §  2. Subdivision 26-b of section 364-j of the social services law, as
 added by section 4 of part B of chapter 69  of  the  laws  of  2016,  is
 amended to read as follows:
   26-b. Managed care providers shall not require prior authorization for
 [an  initial  or  renewal  prescription  for buprenorphine or injectable
 naltrexone  for  detoxification  or  maintenance  treatment  of   opioid
 addiction  unless  the prescription is for a non-preferred or non-formu-
 lary form of the drug or as otherwise required by section 1927(k)(6)  of
 the  Social  Security Act] ANY BUPRENORPHINE PRODUCTS, METHADONE OR LONG
 ACTING INJECTABLE NALTREXONE FOR DETOXIFICATION OR MAINTENANCE TREATMENT
 OF A SUBSTANCE USE DISORDER PRESCRIBED ACCORDING TO  GENERALLY  ACCEPTED
 NATIONAL  PROFESSIONAL  GUIDELINES  FOR THE TREATMENT OF A SUBSTANCE USE
 DISORDER.
   § 3. Subdivision 10 of section 273 of the public health law, as  added
 by  section 5 of part B of chapter 69 of the laws of 2016, is amended to
 read as follows:
   10. Prior authorization shall not  be  required  for  [an  initial  or
 renewal  prescription  for  buprenorphine  or  injectable naltrexone for
 detoxification or maintenance treatment of opioid addiction  unless  the

  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
              

                       [ ] is old law to be omitted.
                                                            LBD10713-07-0

 A. 9634                             2

 prescription  is  for a non-preferred or non-formulary form of such drug
 as otherwise required by section 1927(k)(6) of the Social Security  Act]
 ANY BUPRENORPHINE PRODUCTS, METHADONE OR LONG ACTING INJECTABLE NALTREX-
 ONE  FOR  DETOXIFICATION  OR  MAINTENANCE  TREATMENT  OF A SUBSTANCE USE
 DISORDER PRESCRIBED ACCORDING TO  GENERALLY  ACCEPTED  NATIONAL  PROFES-
 SIONAL GUIDELINES FOR THE TREATMENT OF A SUBSTANCE USE DISORDER.
   §  4.  This  act shall take effect on the ninetieth day after it shall
 have become a law; provided, however, that the amendments to subdivision
 26-b of section 364-j of the social services law made by section two  of
 this  act  shall  not  affect  the  repeal of such section, and shall be
 deemed repealed therewith.